Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Adds Two For Biotech

August 13, 2007 | A version of this story appeared in Volume 85, Issue 33

Lonza has made two additions to its product capabilities to support biotech research. In one development, it has introduced a new line, dubbed Poietics, of human adipose-derived stem cells for use in adult stem cell research. The new stem cell line will provide research laboratories with ready-to-use cells and media for research in areas such as tissue repair, wound healing, cell differentiation, osteoporosis, insulin resistance, or obesity. The system uses cryopreserved normal human adipose-derived stem cells and an optimized growth media kit for cell growth and expansion, which Lonza makes and sells through a commercial license with cell-therapy specialists Cytori Therapeutics. Separately, Lonza has acquired from Zyentia Ltd. all assets relating to its AggreSolve technology, an in silico protein analysis platform used to solve the problems posed by protein aggregation in the selection and development of biopharmaceuticals. The purchase price was not disclosed. The technology will be incorporated into Lonza Biopharmaceuticals' mammalian R&D business, forming a new division, Advanced Protein Technologies. The unit will continue to operate out of its current laboratories based in Cambridge, England.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.